Correction: Open-label evaluation of oral trehalose in patients with neuronal ceroid lipofuscinoses (Journal of Neurology, (2025), 272, 1, (94), 10.1007/s00415-024-12790-7)

In the original version of this article, under the ‘Method’ section in third sentence of the section ‘3AL‑CLN36 study design’, website was mistakenly cited. This sentence, which previously read as To minimize variability in an open, uncontrolled trial, we used a commercially available dose (4 g/day) of Citoplas® (Farmacap, www.farmacap.it), the only GMP-certified formulation of trehalose, used to limit potential side effects in a frail population. but should have read as To minimize variability in an open, uncontrolled trial, we used a commercially available dose (4 g/day) of Farmacap di Capponi Avanzino—https://farmaenergy.com/it/citoplas-integratore-sistema-nervoso-cervello-memoria.html?search_query=Cito&fast_search=fs, the only GMP-certified formulation of trehalose, used to limit potential side effects in a frail population.